Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress

– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 – – 15 ZEVASKYN treatments completed since launch, including six during Q3 – - QTC network expanded to eight sites; four centers have completed patient treatments – - ZEVASKYN NTAP status became effective October 1, 2026 – - $134.9 million in cash, cash equivalents and short-term investments as of September 30, 2026 – - Separately announced acquisition of Phase 3-ready APT-1011 in eosinophilic esophagitis (EoE) and $30 million PIPE financing – CLEVELAND, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc....